HRP20090453T1 - Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptora - Google Patents
Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptora Download PDFInfo
- Publication number
- HRP20090453T1 HRP20090453T1 HR20090453T HRP20090453T HRP20090453T1 HR P20090453 T1 HRP20090453 T1 HR P20090453T1 HR 20090453 T HR20090453 T HR 20090453T HR P20090453 T HRP20090453 T HR P20090453T HR P20090453 T1 HRP20090453 T1 HR P20090453T1
- Authority
- HR
- Croatia
- Prior art keywords
- benzoimidazol
- phenyl
- disorder
- pyridin
- ylmethyl
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title claims 2
- 108091008681 GABAA receptors Proteins 0.000 title claims 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000008673 vomiting Effects 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- WJGWWTHPHXQRTA-UHFFFAOYSA-N 1-[1-(3-pyrazin-2-ylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CN=CC=N1 WJGWWTHPHXQRTA-UHFFFAOYSA-N 0.000 claims 1
- IWPABMQRXNLQAO-UHFFFAOYSA-N 1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CN=C1 IWPABMQRXNLQAO-UHFFFAOYSA-N 0.000 claims 1
- IITIYOZAQGTVPC-UHFFFAOYSA-N 1-[1-(3-pyrimidin-5-ylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CN=CN=C1 IITIYOZAQGTVPC-UHFFFAOYSA-N 0.000 claims 1
- MMVFDEGKHUCZNU-UHFFFAOYSA-N 1-[1-[3-(2,4-dimethoxypyrimidin-5-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=NC(OC)=NC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)N)=C1 MMVFDEGKHUCZNU-UHFFFAOYSA-N 0.000 claims 1
- NBPXEHLTPRERML-UHFFFAOYSA-N 1-[1-[3-(2-fluoropyridin-3-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CN=C1F NBPXEHLTPRERML-UHFFFAOYSA-N 0.000 claims 1
- VARISCAAVFWAFZ-UHFFFAOYSA-N 1-[1-[3-(2-methoxypyridin-3-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound COC1=NC=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)N)=C1 VARISCAAVFWAFZ-UHFFFAOYSA-N 0.000 claims 1
- JMLWUZSYPSJZGT-UHFFFAOYSA-N 1-[1-[3-(5-chloro-1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=NC=C(Cl)S1 JMLWUZSYPSJZGT-UHFFFAOYSA-N 0.000 claims 1
- VTSVDTAXNRKQFF-UHFFFAOYSA-N 1-[1-[3-(6-fluoropyridin-3-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(F)N=C1 VTSVDTAXNRKQFF-UHFFFAOYSA-N 0.000 claims 1
- ZOVKSGHMLZHIIZ-UHFFFAOYSA-N 1-[1-[3-(6-hydrazinylpyridin-3-yl)phenyl]benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(N)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=C(NN)N=C1 ZOVKSGHMLZHIIZ-UHFFFAOYSA-N 0.000 claims 1
- UKYUDSJMQZYWIA-UHFFFAOYSA-N 1-phenyl-n-[[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methyl]methanamine Chemical compound C=1C=CC=CC=1CNCC(C=C1N=C2)=CC=C1N2C(C=1)=CC=CC=1C1=NC=CS1 UKYUDSJMQZYWIA-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010016276 Fear of animals Diseases 0.000 claims 1
- 208000002091 Febrile Seizures Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033892 Paraplegia Diseases 0.000 claims 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010066962 Procedural nausea Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- NIAGYMSBCDVDRM-UHFFFAOYSA-N [1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methanamine Chemical compound C1=NC2=CC(CN)=CC=C2N1C(C=1)=CC=CC=1C1=NC=CS1 NIAGYMSBCDVDRM-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 201000002426 animal phobia Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- ARZIWYMXKAJNHC-UHFFFAOYSA-N n,n-dibenzyl-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C=1C=C2N(C=3C=C(C=CC=3)C=3C=NC=CC=3)C=NC2=CC=1C(C)N(CC=1C=CC=CC=1)CC1=CC=CC=C1 ARZIWYMXKAJNHC-UHFFFAOYSA-N 0.000 claims 1
- FOOUCLZBBJESCC-UHFFFAOYSA-N n,n-dimethyl-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]methanamine Chemical compound C1=NC2=CC(CN(C)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CN=C1 FOOUCLZBBJESCC-UHFFFAOYSA-N 0.000 claims 1
- XKHUFZZVVIQKAQ-UHFFFAOYSA-N n,n-dimethyl-1-[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methanamine Chemical compound C1=NC2=CC(CN(C)C)=CC=C2N1C(C=1)=CC=CC=1C1=NC=CS1 XKHUFZZVVIQKAQ-UHFFFAOYSA-N 0.000 claims 1
- BEZWQFDHNMAXGX-UHFFFAOYSA-N n-[1-[1-[3-(2,4-dimethoxypyrimidin-5-yl)phenyl]benzimidazol-5-yl]ethyl]formamide Chemical compound COC1=NC(OC)=NC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)NC=O)=C1 BEZWQFDHNMAXGX-UHFFFAOYSA-N 0.000 claims 1
- IIDSYIHWNFIJKJ-UHFFFAOYSA-N n-[1-[1-[3-(2-fluoropyridin-3-yl)phenyl]benzimidazol-5-yl]ethyl]formamide Chemical compound C1=NC2=CC(C(NC=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CN=C1F IIDSYIHWNFIJKJ-UHFFFAOYSA-N 0.000 claims 1
- NRZYATBXGSHEST-UHFFFAOYSA-N n-[1-[1-[3-(2-methoxypyridin-3-yl)phenyl]benzimidazol-5-yl]ethyl]formamide Chemical compound COC1=NC=CC=C1C1=CC=CC(N2C3=CC=C(C=C3N=C2)C(C)NC=O)=C1 NRZYATBXGSHEST-UHFFFAOYSA-N 0.000 claims 1
- UURCMGBEZFJDOZ-UHFFFAOYSA-N n-[[1-(3-pyridin-2-ylphenyl)benzimidazol-5-yl]methyl]acetamide Chemical compound C1=NC2=CC(CNC(=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CC=N1 UURCMGBEZFJDOZ-UHFFFAOYSA-N 0.000 claims 1
- WWWRMEOJCUCABV-UHFFFAOYSA-N n-[[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methyl]acetamide Chemical compound C1=NC2=CC(CNC(=O)C)=CC=C2N1C(C=1)=CC=CC=1C1=NC=CS1 WWWRMEOJCUCABV-UHFFFAOYSA-N 0.000 claims 1
- GWXALXVNVINHIP-UHFFFAOYSA-N n-[[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methyl]ethanamine Chemical compound C1=NC2=CC(CNCC)=CC=C2N1C(C=1)=CC=CC=1C1=NC=CS1 GWXALXVNVINHIP-UHFFFAOYSA-N 0.000 claims 1
- FGKPWAWZFDUSDZ-UHFFFAOYSA-N n-[[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methyl]formamide Chemical compound C1=NC2=CC(CNC=O)=CC=C2N1C(C=1)=CC=CC=1C1=NC=CS1 FGKPWAWZFDUSDZ-UHFFFAOYSA-N 0.000 claims 1
- WBFXCSSYQVCGJV-UHFFFAOYSA-N n-benzyl-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C=1C=C2N(C=3C=C(C=CC=3)C=3C=NC=CC=3)C=NC2=CC=1C(C)NCC1=CC=CC=C1 WBFXCSSYQVCGJV-UHFFFAOYSA-N 0.000 claims 1
- IZJJSDXPAYRTEX-UHFFFAOYSA-N n-benzyl-1-phenyl-n-[[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methyl]methanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=C2N=CN(C2=CC=1)C=1C=C(C=CC=1)C=1SC=CN=1)CC1=CC=CC=C1 IZJJSDXPAYRTEX-UHFFFAOYSA-N 0.000 claims 1
- BVTLCOAEDRZKEN-UHFFFAOYSA-N n-ethyl-n-[[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methyl]ethanamine Chemical compound C1=NC2=CC(CN(CC)CC)=CC=C2N1C(C=1)=CC=CC=1C1=NC=CS1 BVTLCOAEDRZKEN-UHFFFAOYSA-N 0.000 claims 1
- WSERYBZHBJHRSL-UHFFFAOYSA-N n-methoxy-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanamine Chemical compound C1=NC2=CC(C(C)NOC)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CN=C1 WSERYBZHBJHRSL-UHFFFAOYSA-N 0.000 claims 1
- KAQZSDGTCKZAPH-UHFFFAOYSA-N n-methyl-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]methanamine Chemical compound C1=NC2=CC(CNC)=CC=C2N1C(C=1)=CC=CC=1C1=CC=CN=C1 KAQZSDGTCKZAPH-UHFFFAOYSA-N 0.000 claims 1
- CKLMMAQWWYMBIE-UHFFFAOYSA-N n-methyl-1-[1-[3-(1,3-thiazol-2-yl)phenyl]benzimidazol-5-yl]methanamine Chemical compound C1=NC2=CC(CNC)=CC=C2N1C(C=1)=CC=CC=1C1=NC=CS1 CKLMMAQWWYMBIE-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- -1 trifluoromethoxy, hydrazino Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj opće formule (I): (I) ili njegov N-oksid, ili bilo koji njegov izomer ili bilo koja mješavina njegovih izomera, ili njegova farmaceutski prihvatljiva sol, naznačen time, da Ra, Rb i Rc nezavisno jedan od drugoga svaki predstavlja vodik, alkil, cikloalkil, cikloalkilalkil, alkenil, alkinil, hidroksi, alkoksi, alkoksialkil, arilalkil, formil, alkilkarbonil ili alkoksialkilkarbonil; Rd predstavlja heteroarilnu skupinu; koja heteroarilna skupina je po potrebi supstituirana sa jednim ili više supstituenata nezavisno odabranih iz skupine koja se sastoji od: halo, hidroksi, R'R''N-, R'R''N-alkil, cijano, nitro, trifluorometil, trifluorometoksi, hidrazino, alkoksi, cikloalkoksi, alkil, cikloalkil, cikloalkilalkil, alkenil, i alkinil; gdje su R' i R'' nezavisno jedan od drugoga vodik ili alkil. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Spoj opće formule (I):
[image]
(I)
ili njegov N-oksid, ili bilo koji njegov izomer ili bilo koja mješavina njegovih izomera, ili njegova farmaceutski prihvatljiva sol,
naznačen time, da
Ra, Rb i Rc nezavisno jedan od drugoga svaki predstavlja vodik, alkil, cikloalkil, cikloalkilalkil, alkenil, alkinil, hidroksi, alkoksi, alkoksialkil, arilalkil, formil, alkilkarbonil ili alkoksialkilkarbonil;
Rd predstavlja heteroarilnu skupinu;
koja heteroarilna skupina je po potrebi supstituirana sa jednim ili više supstituenata nezavisno odabranih iz skupine koja se sastoji od:
halo, hidroksi, R’R’’N-, R’R’’N-alkil, cijano, nitro, trifluorometil, trifluorometoksi, hidrazino, alkoksi, cikloalkoksi, alkil, cikloalkil, cikloalkilalkil, alkenil, i alkinil;
gdje su R’ i R’’ nezavisno jedan od drugoga vodik ili alkil.
2. Spoj prema zahtjevu 1, naznačen time, da Ra predstavlja vodik, alkil ili arilalkil.
3. Spoj prema zahtjevima 1 ili 2, naznačen time, da Rb predstavlja vodik, alkil, alkoksi, arilalkil, formil ili alkilkarbonil.
4. Spoj prema bilo kojem od zahtjeva 1-3, naznačen time, da Rc predstavlja vodik ili alkil.
5. Spoj prema bilo kojem od zahtjeva 1-4, naznačen time, da Rd predstavlja a heteroarilnu skupinu odabranu između tiazolil, piridil, pirimidil i pirazinil;
koja heteroarilna skupina je po potrebi supstitutuirana sa jednim ili više supstituenata nezavisno odabranih iz skupine koja se sastoji od:
halo, hidrazino i alkoksi.
6. Spoj prema zahtjevu 1, naznačen time, da je
C-[1-(3-Tiazol-2-il-fenil)-1H-benzoimidazol-5-il]-metilamin;
C-[1-(3-Piridin-3-il-fenil)-1H-benzoimidazol-5-il]-metilamin;
C-[1-(3-[6-Fluoro-piridin-3-il]-fenil)-1H-benzoimidazol-5-il]-metilamin;
C-[1-(3-[Piridin-2-il]-fenil)-1H-benzoimidazol-5-il]-metilamin;
C-[1-(3-Pirazin-2-il-fenil)-1H-benzoimidazol-5-il]-metilamin;
1-[1-(3-Pirazin-2-il-fenil)-1H-benzoimidazol-5-il]-etilamin;
1-[1-(3-Piridin-3-il-fenil)-1H-benzoimidazol-5-il]-etilamin;
1-{1-[3-(6-Fluoro-piridin-3-il)-fenil]-1H-benzoimidazol-5-il}-etilamin;
1-{1-[3-(6-Hidrazino-piridin-3-il)-fenil]-1H-benzoimidazol-5-il}-etilamin;
1-[1-(3-Pirimidin-5-il-fenil)-1H-benzoimidazol-5-il]-etilamin;
N-[1-(3-Tiazol-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-acetamid;
N-[1-(3-Piridin-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-acetamid;
N-(1-{1-[3-(2-Fluoro-piridin-3-il)-fenil]-1H-benzoimidazol-5-il}-etil)-formamid;
N-(1-{1-[3-(2-Metoksi-piridin-3-il)-fenil]-1H-benzoimidazol-5-il}-etil)-formamid;
N-(1-{1-[3-(2,4-Dimetoksi-pirimidin-5-il)-fenil]-1H-benzoimidazol-5-il}-etil)-formamid;
1-{1-[3-(2,4-Dimetoksi-pirimidin-5-il)-fenil]-1H-benzoimidazol-5-il}-etilamin;
1-{1-[3-(2-Metoksi-piridin-3-il)-fenil]-1H-benzoimidazol-5-il}-etilamin;
1-{1-[3-(2-Fluoro-piridin-3-il)-fenil]-1H-benzoimidazol-5-il}-etilamin;
Metil-[1-(3-piridin-3-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
Dimetil-[1-(3-piridin-3-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
Benzil-{1-[1-(3-piridin-3-il-fenil)-1H-benzoimidazol-5-il]-etil}-amin;
Dibenzil-{1-[1-(3-piridin-3-il-fenil)-1H-benzoimidazol-5-il]-etil}-amin;
Metil-[1-(3-tiazol-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
Dimetil-[1-(3-tiazol-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
Etil-[1-(3-tiazol-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
Dietil-[1-(3-tiazol-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
Benzil-[1-(3-tiazol-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
Dibenzil-[1-(3-tiazol-2-il-fenil)-1H-benzoimidazol-5-ilmetil]-amin;
O-Metil-N-{1-[1-(3-piridin-3-il-fenil)-1H-benzoimidazol-5-il]-etil}-hidroksilamin;
N-{1-[3-(tiazol-2-il)-fenil]-1H-benzoimidazol-5-ilmetil}-formamid;
1-{1-[3-(5-Chloro-tiazol-2-il)-fenil]-1H-benzoimidazol-5-il}-etilamin;
ili njegov N-oksid, bilo koji od njegovih izomera ili bilo koja mješavina njegovih izomera, ili njegova farmaceutski prihvatljiva sol.
7. Farmaceutski pripravak, naznačen time da sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-6, njegov N-oksid, bilo koji od njegovih izomera ili bilo koju mješavinu njegovih izomera, ili njegovu farmaceutski prihvatljivu sol, zajedno sa barem jednim farmaceutski prihvatljivim nosačem, ekscipijentom ili razrjeđivačem.
8. Uporaba kemijskog spoja prema bilo kojem od zahtjeva 1-6, ili njegovog N-oksida, bilo kojeg od njegovih izomera ili bilo koje mješavine njegovih izomera, ili njegove farmaceutski prihvatljive soli, za proizvodnju lijeka.
9. Uporaba prema zahtjevu 8, naznačena time da je za pripravu farmaceutskog pripravka, za liječenje, prevenciju ili ublažavanje bolesti ili poremećaja ili stanja kod sisavaca, uključujući i čovjeka, pri čemu navedena bolest, poremećaj ili stanje reagira na modulaciju iz GABAA receptorskog kompleksa u središnjem živčanom sustavu.
10. Uporaba prema zahtjevu 9, naznačena time da je bolest, poremećaj ili stanje depresija, panični poremećaj sa ili bez agorafobije, agorafobija bez povijesti paničnog poremećaja, strah od životinja i druge fobije, društvena fobija, opsesivno-kompulzivni poremećaj i opći ili posebni poremećaj uslijed depresije, poremećaj uslijed napetosti, post-traumatski stresni poremećaj, akutni stresni poremećaj, poremećaj spavanja, poteškoće s pamćenjem, neuroza, konvulzivni poremećaj, epilepsija, napadaj, konvulzije, febrilne konvulzije kod djece, migrena, poremećaj raspoloženja, depresivni ili bipolarni poremećaj, atipična depresija ili glavni depresivni poremećaj, distimični poremećaj, bipolarni poremećaj, bipolarni poremećaj I, bipolarni manični poremećaj II, ciklotimični poremećaj, psihotični poremećaj, uključujući shizofreniju, neurodegeneracija nastala zbog moždane ishemije, hiperaktivni poremećaj s poteškoćama pažnje, bol, nocicepcija, neuropatska bol, povraćanje, akutno, odgođeno i predvidljivo povraćanje, naročito povraćanje uzrokovano kemoterapijom ili zračenjem, bolest putovanja, post-operativna mučnina, povraćanje, poremećaji prehrane, anorexia nervosa, bulimia nervosa, predmenstrualni sindrom, neuralgija, trigeminalna neuralgija, grčenje mišića, bol zamišljenog uda (kod paraplegičnih pacijenata), učinak zlouporabe droga ili ovisnost, ovisnost o alkoholu, kognitivni poremećaji, Alzheimerova bolest, moždana ishemija, moždani udar, ozljeda glave, zujanje u ušima ili poremećaj srčanog ritma, npr. kod osoba koje pate of učinaka promjene vremenskih zona ili rada u smjenama.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67064705P | 2005-04-13 | 2005-04-13 | |
| DKPA200500530 | 2005-04-13 | ||
| PCT/EP2006/061417 WO2006108800A1 (en) | 2005-04-13 | 2006-04-07 | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090453T1 true HRP20090453T1 (hr) | 2009-10-31 |
Family
ID=36658703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090453T HRP20090453T1 (hr) | 2005-04-13 | 2009-08-21 | Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptora |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7851490B2 (hr) |
| EP (1) | EP1877052B1 (hr) |
| JP (1) | JP2008535891A (hr) |
| KR (1) | KR20070119691A (hr) |
| AU (1) | AU2006233894A1 (hr) |
| CA (1) | CA2604516A1 (hr) |
| CO (1) | CO6241194A2 (hr) |
| DE (1) | DE602006007976D1 (hr) |
| DK (1) | DK1877052T3 (hr) |
| ES (1) | ES2330468T3 (hr) |
| HR (1) | HRP20090453T1 (hr) |
| IL (1) | IL185371A0 (hr) |
| MX (1) | MX2007012624A (hr) |
| NO (1) | NO20075793L (hr) |
| NZ (1) | NZ560939A (hr) |
| PL (1) | PL1877052T3 (hr) |
| PT (1) | PT1877052E (hr) |
| RU (1) | RU2405779C2 (hr) |
| WO (1) | WO2006108800A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1996556T3 (pl) * | 2005-12-05 | 2010-05-31 | Neurosearch As | Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA |
| TWI391381B (zh) | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
| WO2010055124A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| WO2010055126A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| WO2010055125A1 (en) * | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| RU2452486C1 (ru) * | 2011-04-13 | 2012-06-10 | Общество с ограниченной ответственностью "Лечебно-реабилитационный научный центр "Феникс" | Способ фармакотерапии панического расстройства |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK40192D0 (da) | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| HUP9801692A3 (en) | 1995-04-21 | 2001-11-28 | Neurosearch As | Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions |
| AU726447B2 (en) * | 1996-10-21 | 2000-11-09 | Neurosearch A/S | 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators |
| AU742172B2 (en) * | 1997-10-10 | 2001-12-20 | Neurosearch A/S | Benzimidazole compounds, pharmaceutical compositions containing the comp ounds and their use |
| CA2373921A1 (en) * | 1999-06-22 | 2000-12-28 | Neurosearch A/S | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| WO2002050057A1 (en) * | 2000-12-20 | 2002-06-27 | Neurosearch A/S | Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders |
| DE602004011914T2 (de) * | 2003-04-03 | 2008-06-12 | Neurosearch A/S | Benzimidazole derivate und ihre anwendung als gaba a rezeptor komplex modulatoren |
| WO2004087690A2 (en) | 2003-04-03 | 2004-10-14 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex |
| CA2535896A1 (en) * | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors |
| WO2005040131A1 (en) * | 2003-10-23 | 2005-05-06 | Akzo Nobel N.V. | 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| US7419995B2 (en) * | 2004-12-01 | 2008-09-02 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library |
| TWI391381B (zh) | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
-
2006
- 2006-04-07 DE DE602006007976T patent/DE602006007976D1/de active Active
- 2006-04-07 JP JP2008505868A patent/JP2008535891A/ja not_active Abandoned
- 2006-04-07 AU AU2006233894A patent/AU2006233894A1/en not_active Abandoned
- 2006-04-07 ES ES06725630T patent/ES2330468T3/es active Active
- 2006-04-07 MX MX2007012624A patent/MX2007012624A/es active IP Right Grant
- 2006-04-07 RU RU2007137096/04A patent/RU2405779C2/ru not_active IP Right Cessation
- 2006-04-07 PT PT06725630T patent/PT1877052E/pt unknown
- 2006-04-07 WO PCT/EP2006/061417 patent/WO2006108800A1/en active Application Filing
- 2006-04-07 NZ NZ560939A patent/NZ560939A/en not_active IP Right Cessation
- 2006-04-07 KR KR1020077023521A patent/KR20070119691A/ko not_active Application Discontinuation
- 2006-04-07 US US11/887,780 patent/US7851490B2/en not_active Expired - Fee Related
- 2006-04-07 CA CA002604516A patent/CA2604516A1/en not_active Abandoned
- 2006-04-07 EP EP06725630A patent/EP1877052B1/en active Active
- 2006-04-07 DK DK06725630T patent/DK1877052T3/da active
- 2006-04-07 PL PL06725630T patent/PL1877052T3/pl unknown
-
2007
- 2007-08-20 IL IL185371A patent/IL185371A0/en unknown
- 2007-10-09 CO CO07105966A patent/CO6241194A2/es not_active Application Discontinuation
- 2007-11-12 NO NO20075793A patent/NO20075793L/no not_active Application Discontinuation
-
2009
- 2009-08-21 HR HR20090453T patent/HRP20090453T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006108800A1 (en) | 2006-10-19 |
| AU2006233894A1 (en) | 2006-10-19 |
| IL185371A0 (en) | 2008-02-09 |
| US20090036493A1 (en) | 2009-02-05 |
| NZ560939A (en) | 2010-07-30 |
| DK1877052T3 (da) | 2009-10-12 |
| EP1877052B1 (en) | 2009-07-22 |
| DE602006007976D1 (de) | 2009-09-03 |
| ES2330468T3 (es) | 2009-12-10 |
| PL1877052T3 (pl) | 2010-01-29 |
| NO20075793L (no) | 2008-01-14 |
| RU2405779C2 (ru) | 2010-12-10 |
| MX2007012624A (es) | 2008-01-11 |
| RU2007137096A (ru) | 2009-05-20 |
| JP2008535891A (ja) | 2008-09-04 |
| KR20070119691A (ko) | 2007-12-20 |
| CA2604516A1 (en) | 2006-10-19 |
| EP1877052A1 (en) | 2008-01-16 |
| CO6241194A2 (es) | 2011-01-20 |
| US7851490B2 (en) | 2010-12-14 |
| PT1877052E (pt) | 2009-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090453T1 (hr) | Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptora | |
| JP2009530353A5 (hr) | ||
| JP2011528372A (ja) | α７ニコチン性アセチルコリンレセプターインヒビター | |
| JP2016528201A5 (hr) | ||
| JP2017039755A5 (hr) | ||
| EP2604602A4 (en) | HETEROARYL PYRAZOLE DERIVATIVE | |
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| JP2010523654A (ja) | 複素環化合物およびその使用方法 | |
| JP2008542365A5 (hr) | ||
| JP2011524850A5 (hr) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| MX2012007409A (es) | Derivados de benzamida sustituidos. | |
| JP2009511547A5 (hr) | ||
| HRP20151003T1 (hr) | Novi spojevi kao ligandi receptora histamina h3 | |
| HRP20230290T1 (hr) | Derivati triazina za liječenje bolesti u vezi sa neurotrofinima | |
| JP2017535559A (ja) | Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン | |
| PH12013502263A1 (en) | Substituted benzamide derivatives | |
| JP2017503025A (ja) | 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用 | |
| RU2017104264A (ru) | 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные | |
| JP2019537581A5 (hr) | ||
| HRP20171981T1 (hr) | Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti | |
| JP2019537592A5 (hr) | ||
| NZ595627A (en) | Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators | |
| JP2009518292A5 (hr) | ||
| JP2004524279A5 (hr) |